Evidence map›Paper›PMID 33801668›Full record

ArticleJournal of personalized medicine2021

Development of a Digital Research Assistant for the Management of Patients' Enrollment in Oncology Clinical Trials within a Research Hospital.

Alfredo Cesario, Irene Simone, Ida Paris, Luca Boldrini, Armando Orlandi, Gianluca Franceschini, Filippo Lococo, Emilio Bria, Stefano Magno, Antonino Mulè and 13 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Innovations in the Integrated Management of Breast Cancer.Journal of personalized medicine · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Alfredo CesarioOpen Innovation Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0003-4687-0709
Irene SimoneOpen Innovation Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Ida ParisDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Luca BoldriniDepartment of Imaging, Oncological Radiotherapy, and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0002-5631-1575
Armando OrlandiComprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0001-5253-4678
Gianluca FranceschiniDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0002-2950-3395
Filippo LococoThoracic Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0002-9383-5554
Emilio BriaComprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Stefano MagnoCenter for Integrative Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0002-3721-9693
Antonino MulèDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Angela SantoroDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0002-6964-5152
Andrea DamianiDepartment of Imaging, Oncological Radiotherapy, and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0001-8705-3241
Daniele BianchiInformation and Communication Technology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Daniele PicchiInformation and Communication Technology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Guido RasiClinical Trial Center S.p.A., 00168 Roma, Italy.
Gennaro DanieleClinical Trial Center S.p.A., 00168 Roma, Italy.
Alessandra FabiPrecision Medicine in Senology Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Paolo SergiInformation and Communication Technology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Giampaolo TortoraComprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Riccardo MasettiDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Vincenzo ValentiniDepartment of Imaging, Oncological Radiotherapy, and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Marika D'OriaOpen Innovation Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.ORCID 0000-0003-4253-8223
Giovanni ScambiaDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Agostino Gemelli University Polyclinic · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trials in cancer treatment are imperative in enhancing patients' survival and quality of life outcomes. The lack of communication among professionals may produce a non-optimization of patients' accrual in clinical trials. We developed a specific platform, called "Digital Research Assistant" (DRA), to report real-time every available clinical trial and support clinician. Healthcare professionals involved in breast cancer working group agreed nine minimal fields of interest to preliminarily classify the characteristics of patients' records (including omic data, such as genomic mutations). A progressive web app (PWA) was developed to implement a cross-platform software that was scalable on several electronic devices to share the patients' records and clinical trials. A specialist is able to use and populate the platform. An AI algorithm helps in the matchmaking between patient's data and clinical trial's inclusion criteria to personalize patient enrollment. At the same time, an easy configuration allows the application of the DRA in different oncology working groups (from breast cancer to lung cancer). The DRA might represent a valid research tool supporting clinicians and scientists, in order to optimize the enrollment of patients in clinical trials. User Experience and Technology The acceptance of participants using the DRA is topic of a future analysis.

Indexed as

artificial intelligencebreast cancerclinical triallung cancermachine learningoncologypatient enrollmentpersonalized medicineweb app

Identifiers

PMID33801668
PMCPMC8066078
OpenAlexW3148863470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.